Articles On Cynata Therapeutics (ASX:CYP)

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Cynata Therapeutics has started clinical trials of its patented polymer-coated silicon wound dressing, a product dosed with its unique Cymerus mesenchymal stem cells, aimed at treating diabetic foot ulcers.

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

China’s patent office has advised cell therapeutics biotech Cynata Therapeutics that it will be given a patent covering its proprietary Cymerus™ mesenchymal stem cell technology.

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Australian medical device company and global supplier of rapid diagnostic testing devices (RDT), Atomo (ASX: AT1) has scored distribution rights for rapid antigen tests in New Zealand, after being authorised by the New Zealand Ministry of H...

Stem cell biotech business Cynata Therapeutics is boosting its IP protection after being advised it will shortly be granted a Japanese patent for its proprietary Cymerus regenerative stem cell technology.

Cynata Therapeutics has lopped over $800,000 off its tax bill after the company’s cutting-edge cell therapeutic work was deemed eligible for the Federal Government’s research and development incentive.

Stem cell therapy, sometimes called regenerative medicine, is one of the most exciting areas of the life sciences sector right now. It has emerged as a promising alternative approach in many medicine specialties, with some even saying that...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

Cynata Therapeutics has secured a manufacturing services agreement with specialised human cell manufacturing heavyweight, Fujifilm Cellular Dynamics, to produce Cynata’s Cymerus therapeutic stem cell products.

The Cynata Therapeutics Limited (ASX: CYP) share price is in the green today following news of a company deal. Shares in the biotechnology company are up 4.1%, trading at 50 cents at the time of writing. Let’s look at what might be impact...

Cynata Therapeutics (CYP) executes a manufacturing services agreement with FUJIFILM Cellular Dynamics (FCDI) for its Cymerus therapeutic mesenchymal stem cell products The agreement sees FCDI undertaking the product’s technology transfer,...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

Cynata Therapeutics has launched a clinical trial on its Cymerus mesenchymal stem cell product used to treat diabetic foot ulcers in humans. The trial will evaluate safety, wound healing, pain and life quality.

Cynata Therapeutics (CYP) has commenced a clinical trial of its dressing technology (CYP-006TK) in patients with diabetic foot ulcers (DFU) CYP-006TK is a novel polymer-coated silicon wound dressing, seeded with Cymerus mesenchymal stem ce...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Cynata Therapeutics has taken a vital step to conducting a clinical trial on its Cymerus product used to treat diabetic foot ulcers, as it looks to enter a market that could be worth US$10 billion by 2027.

SYDNEY, Oct. 16, 2021 /PRNewswire/ — Ensuring healthy lives and promoting physical and mental well-being is essential to sustainable development. Currently, the world is facing a global health crisis unlike any other. Global health has i...

Clinical-stage biotechnology company, Cynata Therapeutics has received a regulatory tick of approval to continue unchanged its ‘MEND’ clinical trial which is evaluating the company’s proprietary mesenchymal stem cell product in treating pat...

The ASX had a positive end to the week with the ASX 200 gaining 0.87% today taking its weekly gain to 1.9%. All sectors gained with the best being resources which gained nearly 1.7%. Australia’s rise was in line with the broader Asia-Pacifi...

The ASX 200 health stocks index (XHJ) had risen by 0.30% at the time of writing, compared to the broader ASX 200 index which is up by 0.74%. Immuron (ASX:IMC) jumped 19% this morning, after announcing a recent publication of the potential a...

Key highlights Cynata and Fujifilm have entered into a new strategic partnership which includes detailed and agreed core terms for Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata’s Cymerus the...

Biotechnology company Cynata Therapeutics has sealed a partnership agreement with Fujifilm as it moves towards a commercial manufacturing deal for its proprietary Cymerus stem cell therapy products and eyes an accelerated push into the all-...

Biotechnology company Cynata Therapeutics has received high-level coverage of its work on stem cell therapies for heart attacks with a well-known peer-reviewed scientific journal highlighting the successful trial use of its trademark Cymeru...

Cell therapy company Cynata Therapeutics (ASX:CYP) has announced that a scientific paper describing the use of its Cymerus mesenchymal stem cells in a model of myocardial infarction has been published in the peer-reviewed journal Cy...

ASX-listed clinical-stage biotechnology group Cynata Therapeutics is set to notch up yet another patent for its proprietary Cymerus mesenchymal stem cells technology. The company says it has now received the nod from the Patent Office of th...

ShareCafeHidden Gems Webinar Recap – CYP, AT1, NSB & KZA Catch up on the full webinar with presentations from Cynata Therapeutics (ASX: CYP), Atomo Diagnostics (ASX: AT1), NeuroScientific (ASX: NSB) & Kazia Therapeutics (ASX: KZA)...

ShareCafeCell based therapeutic product platform Dr Ross Macdonald – Managing Director and Chief Executive Officer – Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeut...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

ASX-listed clinical-stage stem cell and regenerative medicine group Cynata Therapeutics’ proprietary Cymerus mesenchymal stem cells technology has been impressing the patent overseers in North America as the company looks set to secure yet...

Clinical-stage stem cell and regenerative medicine group Cynata Therapeutics looks to be on the verge of landing a prized patent from the US for its proprietary Cymerus mesenchymal stem cells technology. The company says it expects to recei...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare fi...

Cynata Therapeutics has secured relevant ethics approval for a clinical trial on its Cymerus product for the treatment of diabetic foot ulcers as it looks to enter a market that could be worth US$10 billion within a decade.

Cynata Therapeutics has appointed leading clinical research organisation Dataphram Australia to manage and assist in an upcoming clinical trial for its Cymerus product for treating foot ulcers as it looks to enter a market that could be wor...

Summary The S&P/ASX 200 dropped 7.70 points or 0.11% to 7,300 by afternoon. The market sentiments were dented by coronavirus lockdowns and increased restrictions.  Redbubble was the top percentage gainer, while Gold Road Resources...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

A recent article published in the Advance Science magazine discussed research by Monash University that uncovered a new technique to alter the shape of individual stem cells, which could potentially speed up recovery times for bone replacem...

Escrow Watch is Stockhead’s monthly recap of the ASX companies that are releasing shares currently in escrow (also known as restricted securities) over the coming weeks. ASX shares in escrow are “locked away” and not listed on the bourse so...

Cynata Therapeutics has nailed an exclusive global licence agreement with TekCyte, a leading developer and manufacturer of thin-film polymer coatings, as it looks to conduct a clinical trial for the treatment of diabetic foot ulcers using T...

Summary The ASX 200 continued gaining momentum on Thursday, hitting a fresh record high. The market sentiment got a lift after trade balance and retail sales both rose in April. Energy stocks emerge as top gainers, owing to a rise in...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...